Patient-related determinants of antibiotic use: a systematic review.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 27 11 2017
revised: 17 04 2018
accepted: 28 04 2018
pubmed: 20 5 2018
medline: 26 4 2019
entrez: 20 5 2018
Statut: ppublish

Résumé

We aimed to assess patient-related determinants potentially influencing antibiotic use. Studies published in MEDLINE until 30 September 2015 were searched. We included: qualitative studies describing patients' self-reported determinants of antibiotic use; and quantitative studies on either self-reported or objectively assessed determinants associated with antibiotic use. Whenever possible, reported determinants were categorized as 'barriers' or 'facilitators' of responsible antibiotic use. A total of 87 studies from 33 countries were included. Seventy-five (86.2%) were quantitative and described self-reported (45/75, 60.0%), objectively assessed (20/75, 26.7%) or self-reported and objectively assessed (10/75, 13.3%) patient-related determinants. Twelve (12/87, 13.8%) were qualitative studies or had a qualitative and quantitative component. Eighty-six of the studies (98.8%) concerned the outpatient setting. We identified seven broad categories of determinants having an impact on different aspects of antibiotic use (in descending order of frequency): demographic and socio-economic characteristics, patient-doctor interactions (e.g. counselling), treatment characteristics (e.g. administration frequency), attitudes (e.g. expecting antibiotics), access to treatment (e.g. patients' direct costs), characteristics of the condition for which the antibiotic was prescribed (e.g. duration of symptoms), knowledge (e.g. regarding indications for treatment). Most determinants were classified as 'barriers' to responsible antibiotic use. A large variety of patient-related determinants impact antibiotic use. The most easily 'modifiable' determinants concern patient-doctor interactions, treatment characteristics and knowledge. Data from the inpatient setting and low- and middle-income countries were underrepresented. Further studies should develop and test interventions that take these determinants into account with the ultimate aim of improving responsible use of antibiotics.

Identifiants

pubmed: 29777927
pii: S1198-743X(18)30398-7
doi: 10.1016/j.cmi.2018.04.031
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

48-53

Informations de copyright

Copyright © 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

V Zanichelli (V)

Infection Control Program, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland. Electronic address: veronica.zanichelli.it@gmail.com.

G Tebano (G)

Université de Lorraine, EA 4360 APEMAC, Nancy, France.

I C Gyssens (IC)

Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands; Faculty of Medicine, Research Group of Immunology and Biochemistry, Hasselt University, Hasselt, Belgium.

V Vlahović-Palčevski (V)

Department of Clinical Pharmacology, University Hospital Rijeka, Rijeka, Croatia; University of Rijeka, Medical Faculty, Rijeka, Croatia.

A A Monnier (AA)

Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands; Faculty of Medicine, Research Group of Immunology and Biochemistry, Hasselt University, Hasselt, Belgium; Scientific Centre for Quality of Healthcare (IQ Healthcare), Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.

M Stanic Benic (M)

Department of Clinical Pharmacology, University Hospital Rijeka, Rijeka, Croatia.

S Harbarth (S)

Infection Control Program, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland; Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

M Hulscher (M)

Scientific Centre for Quality of Healthcare (IQ Healthcare), Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.

C Pulcini (C)

Université de Lorraine, EA 4360 APEMAC, Nancy, France; CHRU de Nancy, Service de Maladies Infectieuses et Tropicales, Nancy, France.

B D Huttner (BD)

Infection Control Program, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland; Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH